Customer Service: 866-788-9007

Publication in Cancer Investigation Highlights How Real-World Evidence Shows That Clinicians Appropriately Use the Prognostic 40-GEP Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients

Key Findings Icon

Key Findings

    • The clinical utility of DecisionDx-SCC provides additional information to guide treatment decisions and improve outcomes for cSCC patients

    • Incorporation of DecisionDx-SCC Class results into the patients' risk assessment changed clinicians' overall management strategy when compared to using traditional clinicopathologic risk factors alone

    • This real-world data demonstrates that clearly stratified risk resulting from a DecisionDx-SCC Class result contributes to consistency in a clinicians decision-making process

Treatment decisions for patients with cutaneous squamous cell carcinoma (cSCC) are traditionally based upon clinicopathologic risk factors and staging systems. Due to the accuracy limitations of these resources in predicting poor outcomes, there is a clinically significant need for more accurate methods of risk assessment. The 40-gene expression profile (40-GEP) test was developed to augment metastatic risk prediction of high-risk cSCC patients and has been validated in two independent, multi-center studies involving over 1,000 patients. This study substantiates that the 40-GEP is appropriately utilized by clinicians and that the personalized risk-stratification results are impactful in guiding risk-aligned patient management.

Scroll to Top